Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

411
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
411
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

595
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
595
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

363
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
363
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

527
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
527
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

808
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
808
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

270
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
270

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Cognitive, Functional, and Behavioral Changes After Ventriculoperitoneal Shunt Surgery in Idiopathic Normal Pressure Hydrocephalus: A Multicenter Prospective Study.

World neurosurgery·2026
Same author

Evaluation of metformin for epilepsy prevention or seizure control in people without evidence of diabetes: retrospective cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Seizure prophylaxis in glioma surgery (SPRING): A multi-center, unblinded, randomized trial.

Neuro-oncology practice·2026
Same author

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

British journal of clinical pharmacology·2026
Same author

Seizure prophylaxis in glioma surgery: a synopsis from the SPRING RCT.

Health technology assessment (Winchester, England)·2026
Same author

Reclaiming Functional Neurological Disorder for Rehabilitation Medicine.

Advances in rehabilitation science and practice·2025

Related Experiment Video

Updated: Oct 19, 2025

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

14.2K

Sulthiame monotherapy for epilepsy.

Philip Milburn-McNulty1, Mariangela Panebianco2, Anthony G Marson2,3,4

  • 1Salford Royal Hospital NHS Foundation Trust, Salford, UK.

The Cochrane Database of Systematic Reviews
|September 23, 2021
PubMed
Summary
This summary is machine-generated.

This review found insufficient evidence to support sulthiame (STM) as a monotherapy for epilepsy due to small sample sizes and poor study quality. More research is needed to determine its clinical effectiveness and tolerability.

More Related Videos

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.2K
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

2.9K

Related Experiment Videos

Last Updated: Oct 19, 2025

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

14.2K
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.2K
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

2.9K

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Epilepsy is a common neurological disorder managed with antiepileptic drugs.
  • Sulthiame (STM) is an antiepileptic medication frequently used in Europe and Israel.
  • This review summarizes evidence on STM's efficacy and safety as monotherapy for epilepsy.

Purpose of the Study:

  • To evaluate the effectiveness of sulthiame (STM) as monotherapy for epilepsy.
  • To assess the side effect profile of STM compared to placebo or other antiepileptic drugs.
  • To determine the clinical utility of STM in epilepsy management.

Main Methods:

  • Searched Cochrane Register of Studies, MEDLINE, and other databases up to April 2020.
  • Included randomized controlled monotherapy trials of STM in epilepsy patients of any age.
  • Extracted data on treatment withdrawal, seizure freedom, adverse effects, and quality of life.

Main Results:

  • Four studies with 355 participants were included (BECTS and GTCS diagnoses).
  • STM showed a trend towards fewer dropouts than levetiracetam but inconclusive seizure freedom data.
  • STM was associated with significantly less gingival hyperplasia than phenytoin; adverse event reporting was incomplete.

Conclusions:

  • The current evidence base is insufficient to guide clinical practice for STM monotherapy in epilepsy.
  • Small sample sizes, methodological limitations, and incomplete data hinder definitive conclusions.
  • Further high-quality trials with larger populations and longer follow-up are necessary to establish STM's role in epilepsy treatment.